Article Figures & Data
Figures
- FIGURE 1.
Cellular processing of radioiodinated Nanobody in BT474M1 cells. (A and B) 125I-Nanobody (○) vs. 131I-SGMIB-Nanobody (●): internalized (A) and supernatant (B). (C and D) 131I-IB-Mal-d-GEEEK-Nanobody (□) vs. 125I-SGMIB-Nanobody (▪): internalized (C) and supernatant (D).
- FIGURE 2.
Uptake of radioiodine in athymic mice with BT474M1 xenografts. (A and B) 125I-Nanobody (hatched) vs. 131I-SGMIB-Nanobody (black): tumor (A) and kidneys (B). (C and D) 131I-IB-Mal-d-GEEEK-Nanobody (white) vs. 125I-SGMIB-Nanobody (black): tumor (C) and kidneys (D). *Difference not significant (P > 0.05).
- FIGURE 3.
Tumor–to–normal-tissue ratios in athymic mice bearing subcutaneous BT474M1 xenografts for 131I-IB-Mal-d-GEEEK-Nanobody (○) and 125I-SGMIB-Nanobody (●): liver (A), spleen (B), lungs (C), kidneys (D), heart (E), stomach (F), blood (G), and muscle (H).
Tables
- TABLE 1
Effect of 10 mg of Trastuzumab on Radioiodinated Nanobody Uptake in BT474M1 Xenografts and Normal Tissues
Experiment 1 Experiment 2 125I-Nanobody (185 kBq, 0.6 μg) 131I-SGMIB-Nanobody (185 kBq, 1.0 μg) 125I-SGMIB-Nanobody (93 kBq, 1.6 μg) 131I-IB-Mal-d-GEEK-Nanobody (150 kBq, 0.7 μg) Tissue Not blocked Blocked Not blocked Blocked Not blocked Blocked Not blocked Blocked Liver 7.76 ± 1.56 6.28 ± 0.72 2.65 ± 0.65 2.45 ± 0.34 1.95 ± 0.42 1.72 ± 0.11 13.32 ± 1.75 12.71 ± 0.76 Spleen 3.90 ± 1.77 3.32 ± 0.49 1.13 ± 0.47 1.03 ± 0.37 1.09 ± 0.29 0.92 ± 0.14 2.68 ± 0.38 2.99 ± 0.86 Kidneys 26.05 ± 5.86 21.54 ± 1.09 44.0 ± 12.0 42.30 ± 4.66 34.98 ± 5.57 36.89 ± 5.48 174.8 ± 28.2 197.2 ± 22.4 Blood 10.08 ± 1.47 6.56 ± 0.65* 1.15 ± 0.25 1.04 ± 0.16 0.70 ± 0.10 0.69 ± 0.09 0.69 ± 0.09 0.70 ± 0.09 Tumor 6.39 ± 1.97 2.27 ± 0.22* 24.50 ± 9.89 2.14 ± 0.21* 12.57 ± 2.77 1.26 ± 0.13* 6.23 ± 1.32 0.68 ± 0.06* ↵* Significant blocking effect (P < 0.05).
Data are %ID/g (mean ± SD; n = 5).
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- Optimizing the Therapeutic Index of sdAb-Based Radiopharmaceuticals Using Pretargeting
- Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose 211At-Labeled Anti-HER2 Single-Domain Antibody Fragment
- Site-Specific and Residualizing Linker for 18F Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single-Domain Antibody Fragment
- Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients
- Antibody-Drug Conjugates: A Comprehensive Review
- Radioiodinated Small-Molecule Tyrosine Kinase Inhibitor for HER2-Selective SPECT Imaging
- Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology
- Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma
- 131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment
- Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET